EA201491707A1 - Сульфонамидные производные бензиламина для лечения заболеваний цнс - Google Patents

Сульфонамидные производные бензиламина для лечения заболеваний цнс

Info

Publication number
EA201491707A1
EA201491707A1 EA201491707A EA201491707A EA201491707A1 EA 201491707 A1 EA201491707 A1 EA 201491707A1 EA 201491707 A EA201491707 A EA 201491707A EA 201491707 A EA201491707 A EA 201491707A EA 201491707 A1 EA201491707 A1 EA 201491707A1
Authority
EA
Eurasian Patent Office
Prior art keywords
unsubstituted
substituted
group
ring
benzene ring
Prior art date
Application number
EA201491707A
Other languages
English (en)
Other versions
EA024767B1 (ru
Inventor
Марцин Колачковский
Моника Марцинковская
Адам Буцкий
Томаш Лысаковский
Мацей Павловский
Original Assignee
Адамед Сп. З О.О.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адамед Сп. З О.О. filed Critical Адамед Сп. З О.О.
Publication of EA201491707A1 publication Critical patent/EA201491707A1/ru
Publication of EA024767B1 publication Critical patent/EA024767B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Сульфонамидные производные бензиламина формулы (I), где А представляет собой фенил, незамещенный или замещенный; или 9- или 10-членную бициклическую группу, присоединенную к -(O)-(СН)- через один из ее ароматических атомов углерода, состоящую из бензольного кольца, конденсированного с -членным гетероароматическим кольцом, содержащим 1 или 2 гетероатома, независимо выбранных из группы, состоящей из N и О, где такая бициклическая группа незамещена или замещена, или 5- или 6-членным неароматическим гетероциклическим кольцом, имеющим 1 или 2 атома О, где гетероциклическое кольцо незамещено или замещено одним или несколькими C-С-алкилами; D представляет собой группу, выбранную из фенила, незамещенного или замещенного; нафтила, незамещенного или замещенного; тиофена, незамещенного или замещенного; бициклической группы, состоящей из имидазольного кольца, конденсированного с 5-членным неароматическим карбоциклическим кольцом; бициклической группы, состоящей из бензольного кольца, конденсированного с 5-членным гетероароматическим кольцом, имеющим 1 или 2 гетероатома, независимо выбранных из группы, состоящей из N, О и S, незамещенным или замещенным, и связанной с сульфонамидной группой через один из ароматических атомов углерода бензольного кольца; и бициклической группы, состоящей из бензольного кольца, конденсированного с 5- или 6-членным неароматическим гетероциклическим кольцом, имеющим 1 или 2 гетероатома, независимо выбранных из группы, состоящей из N и О, незамещенным или замещенным, и связанной с сульфонамидной группой через один из атомов углерода бензольного кольца; R представляет собой Н или -СН; х равен 0 или 1; у равен 2 или 3; и к его фармацевтически приемлемым
EA201491707A 2012-03-20 2013-03-20 Сульфонамидные производные бензиламина для лечения заболеваний цнс EA024767B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL39853312 2012-03-20
PCT/IB2013/052204 WO2013140347A1 (en) 2012-03-20 2013-03-20 Sulphonamide derivatives of benzylamine for the treatment of cns diseases

Publications (2)

Publication Number Publication Date
EA201491707A1 true EA201491707A1 (ru) 2015-02-27
EA024767B1 EA024767B1 (ru) 2016-10-31

Family

ID=48325806

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491707A EA024767B1 (ru) 2012-03-20 2013-03-20 Сульфонамидные производные бензиламина для лечения заболеваний цнс

Country Status (15)

Country Link
US (1) US20150051257A1 (ru)
EP (1) EP2828238B1 (ru)
JP (1) JP2015512383A (ru)
KR (1) KR20140135835A (ru)
CN (1) CN104220421A (ru)
AU (1) AU2013237020B2 (ru)
CA (1) CA2866910A1 (ru)
EA (1) EA024767B1 (ru)
HK (1) HK1204603A1 (ru)
IL (1) IL234573A0 (ru)
MX (1) MX2014011315A (ru)
NZ (1) NZ629855A (ru)
UA (1) UA112109C2 (ru)
WO (1) WO2013140347A1 (ru)
ZA (1) ZA201407506B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279136B (zh) * 2016-08-15 2019-06-21 中山大学 治疗中枢神经系统退行性疾病或脑肿瘤的化合物及其应用
US11202776B2 (en) * 2017-05-12 2021-12-21 Takeda Pharmaceutical Company Limited Treatment of gastroparesis with triazaspiro[4.5]decanone
CN110192948B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿腹部热敷贴
CN110192947B (zh) * 2019-05-28 2022-01-04 河南省超亚医药器械有限公司 一种小儿肺部热敷贴

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2005741C (en) 1988-12-26 1998-06-02 Hiroyoshi Hidaka Quinoline sulfonoamino compounds having vessel smooth muscle relaxation activity
JPH0672979A (ja) 1992-06-08 1994-03-15 Hiroyoshi Hidaka アミノベンジル誘導体
JPH06107614A (ja) 1992-09-26 1994-04-19 Arakusu:Kk アリールスルホン酸アミド類またはアリールカルボン酸アミド類及びそれらの薬剤として許容される酸付加塩及びその製造法並びにそれを有効成分とする抗消化性潰瘍剤
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DE19740785A1 (de) 1997-02-21 1998-08-27 Bayer Ag Arylsulfonamide und Analoga
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
DE10053794A1 (de) 2000-10-30 2002-05-08 Bayer Ag Neue Verwendung für Amino- und Amidosulfonamide
US20020127605A1 (en) 2000-11-28 2002-09-12 Hamilton Gregory S. Bisubstituted carbocyclic cyclophilin binding compounds and their use
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
US7723519B2 (en) * 2001-06-07 2010-05-25 Wayne State University Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
CN101817767A (zh) 2009-02-26 2010-09-01 中国科学院上海药物研究所 取代磺酰胺类化合物及其制备方法、药物组合物和应用
CN102458435A (zh) 2009-04-09 2012-05-16 考格尼申治疗股份有限公司 认知衰退的抑制剂

Also Published As

Publication number Publication date
UA112109C2 (uk) 2016-07-25
CN104220421A (zh) 2014-12-17
JP2015512383A (ja) 2015-04-27
IL234573A0 (en) 2014-11-02
AU2013237020A8 (en) 2014-10-09
AU2013237020B2 (en) 2016-10-06
EP2828238B1 (en) 2016-05-25
EP2828238A1 (en) 2015-01-28
CA2866910A1 (en) 2013-09-26
KR20140135835A (ko) 2014-11-26
ZA201407506B (en) 2015-12-23
US20150051257A1 (en) 2015-02-19
NZ629855A (en) 2016-01-29
MX2014011315A (es) 2014-10-17
EA024767B1 (ru) 2016-10-31
HK1204603A1 (zh) 2015-11-27
AU2013237020A1 (en) 2014-09-25
WO2013140347A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
DOP2019000083A (es) COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6140033A2 (es) Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia
AR105820A1 (es) Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
AR070459A1 (es) Derivados de 2-aza-biciclo- [2,2,1] heptano
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
AR073406A1 (es) Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer.
NI201000120A (es) Derivados de ftalazinona
BR112016026596A2 (pt) Derivados de indolin-2-ona ou pirrolo-piridin-2-ona, seu uso, composição farmacêutica e combinação
EA201692048A1 (ru) Дигидротиазин и дигидрооксазин производные, обладающие ингибирующей bace1 активностью
EA201171004A1 (ru) Пиридазиноновые соединения
EA200401613A1 (ru) Лекарственное средство для лечения рака
EA201291409A1 (ru) Производные индолизина, способ их получения и их терапевтическое применение
AR094346A1 (es) Derivados de azaindol como inhibidores de las proteína quinasas
EA201390022A8 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ)
EA201491707A1 (ru) Сульфонамидные производные бензиламина для лечения заболеваний цнс
MX2017012396A (es) Derivado de anillo fusionado de 9 elementos.
AR100715A1 (es) Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
AR115085A1 (es) DERIVADOS DE 3-AMINO-2,4,6-TRIAZINA COMO INHIBIDORES DE LA TIROSINA CINASA DE BRUTON (Btk)
CO2018010787A2 (es) Compuesto de griseofulvina

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU